Tanezumab Dances Through Back Pain Studies With “Acceptable” Safety Answers

In its latest TANGO trial for chronic lower back pain, Eli Lilly and Pfizer’s tanezumab has shown efficacy at 10 mg, but its 5 mg dose missed the statistically significant mark. Vitally, analysts are encouraged by safety data.

Tango
Data from the tanezumab's latest TANGO study was statistically significant in its highest dosage • Source: Shutterstock

More from Clinical Trials

More from R&D